Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?

Simply Wall St.

Apr 28

ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2630658853"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630658853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630658853?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-28 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630658853","market":"us","top_or_hot":-1,"title":"Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?","media":"Simply Wall St.","content":"<div>\n<p>ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/does-immunitybio-ibrx-expanding-anktiva-to-saudi-arabia-rede\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 20:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/does-immunitybio-ibrx-expanding-anktiva-to-saudi-arabia-rede><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/does-immunitybio-ibrx-expanding-anktiva-to-saudi-arabia-rede\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/does-immunitybio-ibrx-expanding-anktiva-to-saudi-arabia-rede","article_id":"2630658853","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/does-immunitybio-ibrx-expanding-anktiva-to-saudi-arabia-rede","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630658853","pubTimestamp":1777378438,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval, in combination with checkpoint inhibitors for metastatic non-small cell lung cancer.\nThis commercial rollout, supported by local partners Biopharma and Cigalah Healthcare, extends ANKTIVA’s reach into a region with a growing burden of bladder and lung cancers and follows a series of recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio(IBRX)将ANKTIVA扩展到沙特阿拉伯是否会重新定义其全球肿瘤战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1.5},"content_text":"ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and, under accelerated approval, in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. This commercial rollout, supported by local partners Biopharma and Cigalah Healthcare, extends ANKTIVA’s reach into a region with a growing burden of bladder and lung cancers and follows a series of recent regulatory authorizations across the U.S., U.K., EU, Macau, and Saudi Arabia. We’ll now examine how ANKTIVA’s Saudi launch across bladder and lung cancer indications could influence ImmunityBio’s broader investment narrative and outlook. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementImmunityBio Investment Narrative RecapTo own ImmunityBio, you have to believe ANKTIVA can move from a single core bladder cancer product to a broader, multi indication franchise in real clinical use. The Saudi launch adds another real world test of that thesis, but it does not change the near term focus on U.S. and EU bladder cancer uptake and the key risk that ANKTIVA remains concentrated in one primary indication if other programs or geographies scale more slowly than hoped. Among recent developments, the European Commission’s conditional marketing authorization for ANKTIVA plus BCG across 33 EU countries looks most connected to the Saudi news. Both highlight that the company is now executing on a multi region rollout, with partners like Accord in Europe and Biopharma and Cigalah in Saudi Arabia, which ties directly into the catalyst of expanding the treated patient base and the risk that adoption and reimbursement vary sharply by market. Yet investors should also weigh the risk that, despite growing approvals, ANKTIVA’s real world adoption outside the U.S. could remain concentrated in a few geographies and... Read the full narrative on ImmunityBio (it's free!)ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and a $786.9 million earnings increase from $-351.4 million today.Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 85% upside to its current price.Exploring Other PerspectivesIBRX 1-Year Stock Price Chart Before this Saudi launch, the most optimistic analysts were already assuming revenue could reach about US$1.6 billion by 2029, which is far more ambitious than the consensus view. If you think about how dependent that outlook is on broad international uptake and not just U.S. use, this new market entry could eventually shift both bullish and baseline narratives in different ways.Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth over 4x more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.No Opportunity In ImmunityBio?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Uncover the next big thing with 24 elite penny stocks that balance risk and reward.Outshine the giants: these 18 early-stage AI stocks could fund your retirement.The latest GPUs need a type of rare earth metal called Neodymium and there are only 32 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}